17.02.2021 • News

Chemours Splits Fluoroproducts Division

US chemical company Chemours announced on Feb. 11 that it had split its Fluoroproducts segment into two distinct businesses during the fourth quarter of 2020.

The previous fluorochemicals reporting unit has become Thermal & Specialized Solutions (TSS), while the fluoropolymers segment has become Advanced Performance Materials (APM). The latter business includes flagship and industry-leading brands such as Teflon, Viton, Krytox and Nafion.

"Our Fluoroproducts business includes two highly customer-centered units that serve distinctly different customers with very specific needs,” said chief operating officer Mark Newman. “The decision to divide these new segments will allow us to capitalize on the unique market opportunities addressed by solutions from both units, while creating new growth opportunities for our customers.”

The company has also appointed new leaders for the TSS and APM businesses. Alisha Bellezza, vice president of fluorochemicals, will become president of TSS, while Denise Dignam, vice president of fluoropolymers, will be president of APM.

The current Fluoroproducts president, Edwin Sparks, will become president of the Titanium Technologies business, replacing Bryan Snell who will retire.

All appointments are effective from Mar. 1, 2021.

Chemours announced on Feb. 11 that it had split its Fluoroproducts segment into...
Chemours announced on Feb. 11 that it had split its Fluoroproducts segment into two businesses during Q4 2020. The previous fluorochemicals reporting unit has become Thermal & Specialized Solutions, while the fluoropolymers segment has become Advanced Performance Materials. (c) Kaleidico

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read